2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2972

Cardiopulmonary Exercise Testing in Patients with Systemic Sclerosis: Unexplored Mechanisms of Dyspnea

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2270

Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis

Epidemiology and Public Health Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2578

Cardiovascular Effects of Etanercept in an Animal Model of Rheumatoid Arthritis: Mechanisms Involved

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2602

CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 3028

CD1d Regulates iNKT Cell Autoreactivity

T cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 3006

Cell-Free Circulating DNA in Systemic Sclerosis: Increased Levels and Global Cytosine Hypomethylation

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2615

Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2645

Changes in Clinical Disease Activity Index and Changes in Sleep Among RA Patients Initiating Disease Modifying Antirheumatic Drugs

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2841

Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2523

Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2621

Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2832

Characterization of Leukocyte Subsets in Ankylosing Spondylitis Patients

Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 2825

Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells

Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 3015

Characterization of the Profibrotic/Antifibrotic Profile of microRNA Contained in Exosomes Isolated from Cultured Normal Human Dermal and Lung Microvascular Endothelial Cells Undergoing Endothelial Mesenchymal Transition in Vitro

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2464

Characterization of the Serum Anti-Citrullinated Protein Antibody Profile in Juvenile Idiopathic Arthritis: Association with Oral Health

Pediatric Rheumatology - Pathogenesis and Genetics Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].